ABUS - Arbutus Biopharma GAAP EPS of -$0.46 misses by $0.33 revenue of $39M beats by $32.88M
- Arbutus Biopharma press release ( NASDAQ: ABUS ): Q4 GAAP EPS of -$0.46 misses by $0.33 .
- Revenue of $39M (+254.5% Y/Y) beats by $32.88M .
- As of December 31, 2022, we had cash, cash equivalents and investments in marketable securities of $184.3 million as compared to $191.0 million as of December 31, 2021.
- Strengthened financial position – cash runway into Q4 2024.
For further details see:
Arbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88M